Tag: NonSmall
Non-small cell lung cancer: symptoms, diagnosis, treatments: Femme Actuelle Le MAG
Leading cause of cancer death in France and worldwide, lung cancer has affected more than 52,000 people in 2023 in France. If its incidence and mortality tend to decrease in…
Lung cancer: what is the difference between small cell cancer and non-small cell cancer? : Current Woman Le MAG
In 2023, the number of new lung cancers has been estimated at 52,777 in France. This cancer is the second most common in men and the third in women. There…
OSE Immunotherapeutics receives €1.5 million in funding from Bpifrance for the development of a companion diagnostic test associated with Tedopi®, its vaccine against non-small cell lung cancer – 06/20/2023 at 18:00
• Funding of 1.5 million euros from Bpifrance – Regional Direction of Nantes within the framework of the “R&D Innovation Loan” program. • Development of a companion diagnostic test to…
OSE Immunotherapeutics provides an update on Tedopi®, a therapeutic cancer vaccine, a potential new reference treatment in non-small cell lung cancer after failure of immunotherapy – 10/20/2022 at 6:00 p.m.
Nantes, France – October 20, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), provides an update on Tedopi®, an immunotherapy for the activation of specific T lymphocytes…
OSE Immunotherapeutics Presents New Data on Tedopi® in Phase 3 Clinical Trial in Patients With Advanced Non-Small Cell Lung Cancer After Failure of Immune Checkpoint Inhibitor Treatment, at ESMO Conference 2022 – 09/05/2022 at 07:30
Nantes, France – September 5, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of new analyzes on the phase 3 Atalante-1 trial of the…